Pfizer and Allergan are reportedly close to announcing a merger that would turn the two into the largest of the Big Pharma companies, Bloomberg has reported. They also would have the largest manufacturing network with possibly more than 100 production facilities. But Pfizer's acquisition record suggests that number would shrink significantly postmerger as it looked for ways to cut costs to pay for the massive deal.
Pfizer has picked up the U.S. rights to Cellectis' closely watched CAR-T asset UCART19. But while Pfizer and Cellectis are working together directly on other immuno-oncology programs, the transfer of the rights to UCART19 was facilitated by a third party: Servier.
Connecticut-based Breckenridge Pharmaceutical is recalling a lot of duloxetine after a single tablet of a stomach-upset drug was found in a bottle of the generic anxiety drug.
Pfizer and Allergan are close to striking a deal that would be the biggest of 2015 by far--and the biggest healthcare deal ever, Bloomberg reports. The price: $370 to $380 per share, or almost $150 billion.
If Pfizer does make a friendly deal for Allergan, CEO Ian Read will be giving up his seat at the helm. That's the word from sources at Pfizer, who told Forbes ' John LaMattina that current negotiations depend on Allergan CEO Brent Saunders taking charge at the combined company.
Médecins Sans Frontières, a global charity and frequent pharma critic, has initiated a worldwide petition calling for Pfizer and GlaxoSmithKline to reduce the prices of their pneumonia vaccines to $5 per child--for all three doses--in emerging markets and for humanitarian organizations.
Merck KGaA and Pfizer have bagged FDA breakthrough therapy designation for avelumab, the pair's anti-PD-L1 monoclonal antibody. And while the immunotherapy is lagging behind rivals' PD-1 and PD-L1 drugs in some indications, Merck KGaA and Pfizer think the breakthrough status could help them steal a lead in metastatic Merkel cell carcinoma.
The history of both Pfizer and Allergan suggests that a merger would mean headcount across the board would be trimmed and that the manufacturing network would be in line early for a haircut.
Dr. Freda Lewis-Hall is the chief medical officer at Pfizer and one of the company's most recognized ambassadors. She's an outspoken advocate for Pfizer and the pharma industry in general, a champion of patient empowerment and a TV medical advice star. FiercePharmaMarketing recently conducted an email interview with the psychiatrist, who also serves by Obama administration appointment to the Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI).
Throughout the tough times faced by the British biopharma industry, the country could always point to its scientific excellence as a source of pride. Now, with more money swilling around, the sector should be enjoying better days, yet as financial woes have receded another resource shortage has come into view: The United Kingdom appears to be running low on scientists.